| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC
|
Li, Wei
|
|
|
167 |
C |
p. 25-33
|
artikel
|
| 2 |
Contents
|
|
|
|
167 |
C |
p. v-vi
|
artikel
|
| 3 |
Corrigendum to “Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands” [Lung Cancer 162C (2021) 61–70]
|
Evers, Jelle
|
|
|
167 |
C |
p. 107
|
artikel
|
| 4 |
Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers
|
Mc Leer, Anne
|
|
|
167 |
C |
p. 98-106
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
167 |
C |
p. iii
|
artikel
|
| 6 |
EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients
|
Liu, Xianping
|
|
|
167 |
C |
p. 78-86
|
artikel
|
| 7 |
EpCAM-positive disseminated cancer cells in bone marrow impact on survival of early-stage NSCLC patients
|
Mederer, Tobias
|
|
|
167 |
C |
p. 73-77
|
artikel
|
| 8 |
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
|
Scherpereel, Arnaud
|
|
|
167 |
C |
p. 8-16
|
artikel
|
| 9 |
Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study
|
Paz-Ares, Luis
|
|
|
167 |
C |
p. 41-48
|
artikel
|
| 10 |
Geographic distribution of malignant mesothelioma incidence and survival in Australia
|
Cameron, Jessica K.
|
|
|
167 |
C |
p. 17-24
|
artikel
|
| 11 |
Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib
|
Zhou, Yuling
|
|
|
167 |
C |
p. 58-64
|
artikel
|
| 12 |
Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials
|
Koller, Michael
|
|
|
167 |
C |
p. 65-72
|
artikel
|
| 13 |
Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice
|
Steeghs, Elisabeth M.P.
|
|
|
167 |
C |
p. 87-97
|
artikel
|
| 14 |
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis
|
Torasawa, Masahiro
|
|
|
167 |
C |
p. 49-57
|
artikel
|
| 15 |
Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study
|
Garcia, Betzabel N. Cajiao
|
|
|
167 |
C |
p. 1-7
|
artikel
|
| 16 |
Tumor-associated CD163+ macrophage as a predictor of tumor spread through air spaces and with CD25+ lymphocyte as a prognostic factor in resected stage I lung adenocarcinoma
|
Yoshida, Chihiro
|
|
|
167 |
C |
p. 34-40
|
artikel
|
Tijdschrift beschrijving